NCT05431582 - Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | Biotech Hunter

Timeline

Start Date

December 14, 2022

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions

TumorsOvarian CancerBreast CancerLung CancerPancreatic Cancer

Interventions

DRUG

ZN-c3

Given by PO 1 time a day with a glass (about 8 ounces) of water

DRUG

Bevacizumab

Given by vein over about 30-60 minutes on Day 1 of each cycle

DRUG

Pembrolizumab

Given by vein over 30-60 minutes on Day 1 of each cycle.